XOMA (NASDAQ: XOMA)
XOMA Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
XOMA Company Info
XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
News & Analysis
XOMA Revenue Jumps 39% in Fiscal Q2
3 Best Healthcare Stocks of 2017
The key to big gains last year? Start off small.
3 Biotech Stocks That Turned $1,000 Into More Than $5,000 This Year
These three biotech stocks helped a lot of investors get rich this year. Are there more gains ahead?
Why XOMA Shares Are Crashing
XOMA's third quarter financial results failed to ignite investor enthusiasm today.
3 Biotech Stocks 50% (or More) Off Their 5-Year Highs That Could Double
Wall Street has cast these three biotech stocks to the proverbial scrap heap over the past five years, but a big rebound may soon be in order.
Why XOMA Corp. Shares Rocketed Higher
XOMA shareholders press the launch button after the company begins the (approximate) countdown to a major news event.
How 1 Sentence Caused XOMA Corp. Shares to Explode Higher
XOMA Corp. released its first-quarter earnings results after the closing bell last night, but it was a single sentence from management, not its actually quarterly results, that has investors so excited today.
3 Things You Need to Know About XOMA Corp.
Thinking of investing in this high risk, high reward biotech stock? Here are three things you need to know first.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.